P-285 Treatment outcomes with sorafenib in advanced hepatocellular carcinoma: A single-center retrospective study

Abstract

response (Mandard score 1 and 2). Variables which met the cut-off criteria were used to fit multivariate logistic regression models combining clinical variables (age, gender, T-stage and N-stage) with imaging features. Performance of the combined models was compared with that of baseline clinical model and the area under the curve (AUC), and two-tailed p values were reported.Results: 37 patients (6 female, 31 male, median 65 years, range 41-80) were included in this analysis. 13/37 patients achieved a pathological response. Diffusion-weighted MTD at Timepoint_1 (OR 0.33, 95%CI 0.14-0.81, p 0.02) and T2-weighted kurtosis at Timepoint_2 (OR 0.09, 95%CI 0.01-0.91, p 0.04) were associated with pathological response. These statistically improved the predictive performance of the clinical model (AUC 0.88 and 0.94, respectively versus 0.75 for baseline clinical model).Conclusions: Diffusion-weighted maximal tumour dimension at week-3 and T2weighted kurtosis on neoadjuvant treatment completion have the potential to improve the predictive value of clinical models for response to treatment, but would require external validation in subsequent studies.